Beyond Molecular Residual Disease: The Gastroseed Artificial Intelligence (AI) Paradigm for Early Prediction of Metastatic Progression After Curative Gastrointestinal Cancer Surgery
Journal of Surgery Research and Practice · 29.06.2026 · 7 (2) · 1-13
DOI: 10.46889/jsrp.2026.7211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgery Research and Practice, online erschienen am 29.06.2026. Verfasst von João Rêgo Araújo und 2 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben.
Abstract (Originalsprache)
Background
Circulating tumor DNA (ctDNA) detection has revolutionized Molecular Residual Disease (MRD) assessment in gastrointestinal cancer, yet the “recurrence paradox” persists some ctDNA-negative patients relapse while ctDNA-positive patients remain disease-free, suggesting that tumor biology alone does not determine metastatic outcomes.
Objective
To propose the GastroSeed-AI paradigm, a systems-oncology framework integrating five biological domains (molecular residual disease, tumor genomics, gut microbiota, host immunometabolic status, and perioperative biology) with artificial intelligence to predict metastatic progression after curative gastrointestinal cancer surgery.
Methods
This is a translational narrative synthesis integrating current evidence from molecular oncology, surgical biology, microbiome research, immunometabolism, and machine learning. We conducted a comprehensive literature search across PubMed, Scopus, and Web of Science (2018-2026) using search terms including “circulating tumor DNA,” “molecular residual disease,” “gastrointestinal neoplasms,” “gut microbiota,” “immunometabolic status,” and “perioperative complications.” Evidence was synthesized thematically and integrated into a conceptual framework.
Results
The GastroSeed-AI paradigm proposes that metastatic recurrence results from the interaction between the “seed” (tumor cells with metastatic potential) and the “soil” (host environment). Five biological domains were identified as critical determinants: (1) molecular residual disease as a marker of tumor burden; (2) tumor genomics defining intrinsic metastatic potential; (3) gut microbiota composition influencing immune competence; (4) host immunometabolic status reflecting capacity for tumor control; and (5) perioperative biology creating windows of vulnerability. Artificial intelligence is proposed as the essential tool to synthesize these heterogeneous, high-dimensional datasets into a single actionable risk score.
Conclusion
The GastroSeed-AI paradigm represents a paradigm shift from tumor-centric to systems-oncology approaches in predicting metastatic recurrence. This framework provides a roadmap for prospective validation, computational prototype development, and eventual clinical implementation over a 6-year translational pathway.
Zitieren
APA
Araújo, J. R., Rêgo, A. C. M., & Filho, I. A. (2026). Beyond Molecular Residual Disease: The Gastroseed Artificial Intelligence (AI) Paradigm for Early Prediction of Metastatic Progression After Curative Gastrointestinal Cancer Surgery. Journal of Surgery Research and Practice, 7(2), 1-13. https://doi.org/10.46889/jsrp.2026.7211
Vancouver
Araújo JR, Rêgo ACM, Filho IA. Beyond Molecular Residual Disease: The Gastroseed Artificial Intelligence (AI) Paradigm for Early Prediction of Metastatic Progression After Curative Gastrointestinal Cancer Surgery. Journal of Surgery Research and Practice. 2026;7(2):1-13. doi:10.46889/jsrp.2026.7211
BibTeX
@article{Arajo2026,
author = {Araújo, João Rêgo and Rêgo, Amália Cinthia Meneses and Filho, Irami Araújo},
title = {Beyond Molecular Residual Disease: The Gastroseed Artificial Intelligence (AI) Paradigm for Early Prediction of Metastatic Progression After Curative Gastrointestinal Cancer Surgery},
journal = {Journal of Surgery Research and Practice},
year = {2026},
volume = {7},
number = {2},
pages = {1--13},
doi = {10.46889/jsrp.2026.7211}
}
EUVIMED